Uricase - Enzon

Drug Profile

Uricase - Enzon

Alternative Names: PEG-uricase - Enzon; Urate oxidase - Enzon

Latest Information Update: 29 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gout

Most Recent Events

  • 14 Jan 2014 Biomarkers information updated
  • 26 Aug 1998 No-Development-Reported for Gout in USA (Unknown route)
  • 31 Dec 1994 Phase-I clinical trials for Gout in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top